

The Activation of Mitogen-Activated Protein Kinases in the Optic Nerve
Head in a Model of Ocular Hypertension

Teresa Mammone

A thesis submitted to the University of Adelaide in fulfilment of
Masters of Philosophy (Ophthalmology)

In

The Discipline of Ophthalmology & Visual Sciences, School of Medicine

August 2017

CONTENTS

ABSTRACT	4
DECLARATION.....	6
ACKNOWLEDGMENT	8
ABBREVIATIONS.....	9
INTRODUCTION	10
Anatomy of the visual system	10
Models.....	14
RGC death.....	18
Protein phosphorylation.....	20
MAPK.....	21
Neuroprotection as a treatment strategy for glaucoma	24
HYPOTHESIS AND AIMS	27
Aim 1; Chapter 1.....	27
Aim 2; Chapter 2.....	27
CHAPTER 1.....	28
Statement of Authorship.....	28
EXPRESSION AND ACTIVATION OF MAPK IN THE ONH IN A RAT MODEL OF OCULAR HYPERTENSION.....	30
ABSTRACT	31
INTRODUCTION	33
MATERIALS AND METHODS.....	36
<i>Materials</i>	36
<i>Animals and Procedures</i>	39
<i>Tissue harvesting of ONH for protein and RNA extraction</i>	41
<i>Tissue processing for paraffin embedding</i>	41
<i>Immunohistochemistry</i>	42
<i>Real-time RT-PCR</i>	44
<i>Western immunoblotting</i>	45
<i>Experimental design and statistics</i>	46
RESULTS.....	47
<i>Validation of the model</i>	47
<i>Validation of the MAPK antibodies</i>	47
<i>Choice of fixative for ocular studies</i>	48
<i>P42/44 MAPK</i>	49

<i>SAPK/JNK</i>	57
<i>P38 MAPK</i>	64
DISCUSSION	72
<i>P42/44 MAPK</i>	72
<i>SAPK/JNK</i>	75
<i>P38 MAPK</i>	77
CONCLUSIONS	79
DECLARATION.....	81
<i>Ethics approval</i>	81
<i>Availability of data and materials</i>	81
<i>Conflict of interests</i>	81
<i>Funding</i>	81
<i>Author contribution</i>	82
<i>Acknowledgments</i>	82
REFERENCES	83
SUPPLIMENTAL FIGURES	90
CHAPTER 2 PRELUDE	93
Is that the end of MAPK in the ONH?	93
CHAPTER 2.....	94
Statement of Authorship.....	94
IMPROVED IMMUNOHISTOCHEMICAL DETECTION OF PHOSPHORYLATED MAP KINASES IN THE INJURED RAT ONH.....	96
ABSTRACT	97
INTRODUCTION	99
MATERIALS AND METHODS.....	102
<i>Materials</i>	102
<i>Rat model of chronic OHT</i>	105
<i>Tissue collection and processing for paraffin embedding</i>	106
<i>Immunohistochemistry</i>	106
<i>Evaluation of Immunohistochemistry</i>	108
<i>Western Immunoblotting</i>	111
<i>Experimental design</i>	112
RESULTS.....	113
<i>Evaluation of damage profiles</i>	113
<i>Verification of antibody detection of MAPK species by Western immunoblot</i>	114
<i>Immunolabelling of MAPK subtypes</i>	114

<i>P42/44 MAPK</i>	114
<i>SAPK/JNK</i>	119
<i>P38 MAPK</i>	124
<i>Ethics approval</i>	137
<i>Availability of data and materials</i>	137
<i>Conflict of interests</i>	137
<i>Funding</i>	137
<i>Author contribution</i>	138
<i>Acknowledgments</i>	138
SUPPLEMENTAL FIGURES	142
DISCUSSION	149
Context of the study and contribution to current knowledge	149
CONCLUSIONS AND FUTURE STUDIES.....	157
REFERENCES	158

ABSTRACT

Glaucoma is a neurological blinding eye disease, which results from the death of retinal ganglion cells. Although the pathogenesis of glaucoma remains unknown, changes in the tissue microenvironment of the optic nerve head (ONH), where insults are believed to be initiated, will cause signalling alterations in local cells. One important type of signalling involved in the control of cellular functions is protein phosphorylation. This is controlled by the balance between protein kinases and protein phosphatases, which add and remove phosphate groups respectively. One particularly important group of protein kinases is the mitogen-activated protein kinase (MAPK) family, whose activity is known to be altered in neurological diseases.

The first aim of this thesis was to determine whether specific MAPK family members (P42/44 MAPK, SAPK/JNK MAPK and P38 MAPK) were altered in a laser-induced ocular hypertension model, used to simulate the pressure elevation often associated with glaucoma. Techniques used for analysis included immunohistochemistry to observe changes in histopathological activation and location, Western immunoblotting to quantify changes in protein level expression, and real time reverse-transcriptase polymerase chain reaction to establish whether there were any changes in MAPK gene expression.

Total P42/44 MAPK expression was unaffected after intraocular pressure elevation, but a significant increase in its activation was detected in astrocytes in the ONH after 6-24 hours. Active SAPK/JNK was present throughout treated and untreated RGC axons, but accumulated in the ONH at 6-24 hours after pressure elevation, signifying axon transport disruption. P38 MAPK was expressed by a population of microglial cells throughout the retina, ONH and optic nerve, which were significantly increased in number following elevated intraocular pressure. However, this enzyme was only significantly activated in microglia after more than 3 days and

then not in the retina, where it was solely activated in retinal ganglion cell perikarya. These data imply both upregulation and activation of MAPK in the ocular hypertension model, in several distinct locations.

Levels of particular phosphoproteins are readily affected by minor perturbations in cellular homeostasis, as will occur when an animal is killed for tissue procurement. Thus, the second aim of this thesis was to identify whether activated MAPKs could be stabilised in procured tissues by perfusing animals with saline containing phosphatase inhibitors before fixation. Immunohistochemical analysis was used to observe differences in specific staining of phosphorylated MAPKs. The addition of phosphatase inhibitors to the perfusate had no significant effect on control animals or animals where there was a robust demonstration of tissue damage, but this procedure significantly reduced variability and improved clarity of outcome in labelling for activated MAPKs in animals with less extensive tissue damage, likely by stabilising levels of these phosphoproteins. These data suggest that phosphatase inhibitors stabilised phosphorylated MAPK levels and enabled a clearer dissemination of the activation of these enzymes, particularly when associated tissue damage was not extensive.

Having determined that MAPKs isoenzymes were activated in the ONH after sustained ocular hypertension, future work will concentrate on determining whether manipulation of these enzymes could play a useful role in the management of diseases such as glaucoma.

DECLARATION

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree. I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I acknowledge that copyright of published works contained within this thesis resides with the copyright holder(s) of those works. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Teresa Mammone

November 2017

8/9/2017

Re: A1655487, School of Medicine, AHEGS Thesis A... - Mammone, Teresa (Health)

Re: A1655487, School of Medicine, AHEGS Thesis Abstract

Wood, John (Health)

Wed 9/08/2017 1:14 PM

To: graduate centre <graduate.centre@adelaide.edu.au>;

Cc: Mammone, Teresa (Health) <Teresa.Mammone@sa.gov.au>;

📎 1 attachment

Copy of ahegs-thesis-abstract-A1655487.xlsx;

To Graduate Centre

cc Teresa Mammone

I have looked through the attached AHEGS abstract for Teresa Mammone and I am happy with this.

Thank you and best wishes

John W

Abstract:

The aim of this thesis was to investigate the activation of mitogen activated protein kinases (MAPKs) in the optic nerve head in a laser-induced model of ocular hypertension (OHT).

Activation of three distinct sub-groups of MAPKs: P42/44 MAPK, SAPK/JNK and P38 MAPK was proven, by immunohistochemistry, Western immunoblot and reverse-transcriptase polymerase chain reaction.

In addition to this, a more sensitive method of detection for activated MAPKs was developed in order to identify whether the magnitude of the observed activations in the ONH were directly proportional to the degree of tissue damage in the model.

John P. M. Wood, D.Phil,
Senior Research Scientist,
Ophthalmic Research Laboratories,
Level 7, Adelaide Health and Medical Sciences Building,
The University of Adelaide,
North Terrace,
Adelaide,
South Australia 5000

PO Box 14, Rundle Mall,
South Australia 5000

Tel: +61 8 8313 7183

Email: john.wood2@sa.gov.au
john.wood@adelaide.edu.au

From: Teresa Mammone <teresa.mammone@adelaide.edu.au>
Sent: Wednesday, 9 August 2017 1:04 PM
To: graduate centre
Cc: Wood, John (Health)
Subject: A1655487, School of Medicine, AHEGS Thesis Abstract

Hi Dr Wood,

Attached is the AHEGS thesis abstract.

Please review and confirm, by reply of email, you are satisfied with the wording and submission of this abstract and thesis.

Regards
Teresa Mammone

<https://owa.statenetmail.sa.gov.au/owa/#viewmodel=ReadMessageItem&ItemID=AAMkADczNTYzYTgzLWZjODkNGQ5Ni04NmM1LTU2ZDg2N2l...> 1/1

ACKNOWLEDGMENT

The financial support of the Bright Focus Foundation, the Ophthalmic Research Institute of Australia and the National Health and Medical Research Council of Australia are gratefully acknowledged.

My heartfelt appreciation and sincere gratitude goes to the many people who have supported me in achieving the work presented here. Firstly, to Dr John Wood my principle supervisor, for his support, guidance and review of my work, which at times was no doubt challenging. And Dr Glyn Chidlow, for his positive critique. Their mentorship and knowledge in the scientific discipline of ophthalmology is exceptional.

To my work colleague, Mark Daymon, for his support, technical guidance in histology and friendship. Your years of wisdom and guidance through life's journey have provided much reassurance and laughter after the long and challenging working weeks.

To Professor Robert Casson and the supportive network of the Ophthalmic Research Laboratory Julia Winnick, thank you for your support and guidance.

To the Neuropathology Laboratory, Jim, Kathy, Bernice, Yvonne, Serg, Sven, Sofie and Dr Barbara Koszyca, thank you. The competitive nature of our morning tea cryptic crosswords will always be a fond memory.

To my parents Antonio and Maria, brothers Francesco and Vincenzo and sister Christina. My sister-in laws Rita and Katrina, and my beautiful nephews and nieces, Anthony, Valentina, Amelia, Alessandro and Aria. You provided much support and laughter when I needed it the most.

A special mention and my gratitude go to the many people I have had the privilege of meeting through this work and developed life-time friendships. In particular to Dr Andreas Ebnetter, thank you for your assistance in establishing and teaching me the glaucoma model. For all the fun we have shared both here in Adelaide and in Switzerland. I would also like to thank Alisa Kruger and Rebecca Spence for your words of wisdom and encouragement.

ABBREVIATIONS

AD; Alzheimer's disease

APP; Amyloid precursor protein

CNS; Central nervous system

HD; High damage

IOP; Intraocular pressure

LD; Low damage

MAPK; Mitogen-activated protein kinase

MPIs; Minus phosphatase inhibitors

NBF; Neutral buffered formalin containing 4 % formaldehyde

OHT ; Ocular hypertension

ONH; Optic nerve head

P38 MAPK ; P38 mitogen-activated protein kinase

P42/44 MAPK; Extracellular signal-regulated kinases (ERK)

PIs; Phosphatase inhibitors

POAG; Primary open-angle glaucoma

PPIs; Plus phosphatase inhibitors

RGC; Retinal ganglion cells

SAPK/JNK; Stress-activated protein kinase/c-Jun N-terminal kinases